Canaccord analyst Kyle Mikson lowered the firm’s price target on T2 Biosystems to $3 from $12 and keeps a Hold rating on the shares. The firm believes the recent selloff has provided an attractive opportunity to accumulate shares of the company with potential catalysts and notes management could share updates related to their strategies for targeting focused markets.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TTOO:
- T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024
- T2 Biosystems files to sell common stock and warrants, no amount given
- T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity
- T2 Biosystems shareholders vote for CRG debt conversion into equity
- T2 Biosystems Reinforces Market Position with Extended Vizient Agreement
